Zacks Research Upgrades OS Therapies (NYSEAMERICAN:OSTX) to “Hold”

OS Therapies (NYSEAMERICAN:OSTX) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Lake Street Capital dropped their price objective on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

OS Therapies Trading Down 3.8%

NYSEAMERICAN OSTX opened at $1.78 on Thursday. The firm has a market cap of $79.28 million, a price-to-earnings ratio of -1.65 and a beta of -0.95. The company has a 50 day moving average of $1.61 and a 200-day moving average of $1.55. OS Therapies has a 1-year low of $1.15 and a 1-year high of $2.57.

OS Therapies (NYSEAMERICAN:OSTX) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.27) earnings per share for the quarter. On average, analysts forecast that OS Therapies will post 0.16 earnings per share for the current year.

Institutional Trading of OS Therapies

A number of institutional investors have recently bought and sold shares of OSTX. Susquehanna International Group LLP acquired a new stake in OS Therapies during the 3rd quarter worth $29,000. Jane Street Group LLC acquired a new stake in OS Therapies during the 4th quarter worth $39,000. Ground Swell Capital LLC acquired a new stake in OS Therapies during the 3rd quarter worth $40,000. Mercer Global Advisors Inc. ADV acquired a new stake in OS Therapies during the 3rd quarter worth $40,000. Finally, Bridgeway Capital Management LLC acquired a new stake in OS Therapies during the 2nd quarter worth $47,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.